Corbus Pharmaceuticals Holdings, Inc.
CRBP evidence brief
What we can confirm
- BioSniper Score:
- 7.8 / 10
- Market Cap:
- $204.9M
What it means
What to watch
Prepared research question
What matters most for CRBP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CRBP
Corbus Pharmaceuticals Holdings, Inc. (CRBP) is a clinical-stage biopharmaceutical company developing therapies in oncology and obesity, with lead programs including a Nectin-4-targeted ADC (CRB-701) and a peripherally restricted CB1 inverse agonist (CRB-913).
Key risk: Cash runway
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$204.9M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 4 clinical trials for Corbus Pharmaceuticals Holdings, Inc..
Corbus Pharmaceuticals Holdings, Inc. (CRBP) is a clinical-stage biopharmaceutical company developing therapies in oncology and obesity, with lead programs including a Nectin-4-targeted ADC (CRB-701) and a peripherally restricted CB1 inverse agonist (CRB-913).
- Cash & equivalents of $23.4M as of 2026-06-30 [sec].
- Net income of -$35.0M as of 2026-06-30 [sec].
- Shareholders' equity of $102.2M as of 2026-06-30 [sec].
- Completed a $75M public offering in 2025, extending cash runway into 2028 [news · published 2025-11-12].
- Lead oncology candidate CRB-701 (Nectin-4 ADC) has a registrational study (TEMPO-1) expected to initiate enrollment in September 2026 [news · published 2026-07-28].
What works
- CRB-701 demonstrated robust activity in 2L HNSCC and cervical cancer, with an ORR of 47.6% in HNSCC at the 3.6 mg/kg dose [news · published 2025-11-12].
- CRB-913 showed differentiated GI tolerability from the GLP-1 class in Phase 1a and yielded 15 times lower brain penetration than monlunabant in mice [news · published 2026-08-04].
- The company has a clear registration path for CRB-701 in 2L HNSCC and cervical cancer after reaching broad alignment with the FDA [news · published 2026-05-12].
- CANYON-1 Phase 1b study of CRB-913 completed enrollment (n=240) and positive topline data were announced in September 2026 [news · published 2026-09-14].
What to weigh
- The company reported a net loss of -$35.0M for the period ending 2026-06-30 [sec].
- Cash & equivalents of $23.4M as of 2026-06-30 may be limited relative to the costs of advancing multiple Phase 3 programs [sec].
- CRB-701 faces a competitive landscape including Bicycle Therapeutics, Pfizer (PADCEV), and others [pipeline].
- CRB-913 is in early clinical development (Phase 1b) and has not yet demonstrated efficacy in a registrational study [news · published 2026-09-14].
From the filings
Quoted directly from source documents.
CRB-701 clinical data at ASCO 2026
“updated data from its Phase 1/2 clinical study of CRB-701 (SYS6002), a next-generation Nectin-4 targeted ADC. The new data demonstrate robust activity in the second line (2L) setting of two solid tumor types that express high levels of Nectin-4 and are primarily driven by human papilloma virus (HPV): oropharyngeal squamous cell carcinoma (OPSCC) and cervical cancer.”
SEC filings · May 26, 2026
CRB-913 CANYON-1 topline data positive
“positive topline data from its CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity”
News · September 14, 2026
CRB-701 registrational study TEMPO-1 initiation
“FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer”
News · July 28, 2026
CRB-913 brain penetration data
“CRB-913 yielded 15 times lower brain penetration than monlunabant in mice”
News · August 4, 2026
Catalyst timeline
- 2026-09-20 · Phase3_Start — Potential start of a Phase 3 study for an undisclosed candidate, possibly CRB-701 or CRB-913.
Risks & what to watch (4)›
Key risks
- Cash runway — Cash & equivalents of $23.4M as of 2026-06-30 may be insufficient to fund all planned Phase 3 programs without additional financing [sec].
- Competitive landscape for CRB-701 — CRB-701 faces competition from multiple companies targeting Nectin-4, including Pfizer's PADCEV [pipeline].
- Early stage of CRB-913 — CRB-913 is only in Phase 1b; no registrational data yet, and obesity market is highly competitive [news · published 2026-09-14].
- Net loss trend — Net income of -$35.0M as of 2026-06-30 indicates ongoing operating losses [sec].
What to watch
- Initiation of TEMPO-1 registrational study for CRB-701 in 2L oropharyngeal cancer, expected September 2026 [news · published 2026-07-28].
- Presentation of CRB-913 topline data at ObesityWeek 2026 [news · published 2026-09-14].
- Potential Phase 3 start for CRB-913 if CANYON-1 data support advancement [catalyst].
- Cash position updates and any new financing rounds given $23.4M cash as of 2026-06-30 [sec].
Sources: Catalysts · News · Pipeline · SEC filings · Generated October 8, 2026 · How we verify sources →
Run Corbus Pharmaceuticals Holdings, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Corbus Pharmaceuticals Holdings, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.24 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
3 buys · 5 sells (180d)
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
106
Total value held
$119.1M
| Holder | Shares | Value |
|---|---|---|
| cormorant asset management, lp | 2,344,971 | $22.0M |
| orbimed advisors llc | 1,737,287 | $16.3M |
| aberdeen group plc | 1,321,750 | $12.4M |
| vanguard capital management llc | 734,106 | $6.9M |
| citadel advisors llc | 727,060 | $6.8M |
| prosight management, lp | 697,108 | $6.5M |
| diadema partners lp | 439,957 | $4.1M |
| stonepine capital management, llc | 383,462 | $3.6M |
| armistice capital, llc | 364,000 | $3.4M |
| renaissance technologies llc | 346,998 | $3.3M |
Showing top 10 of 106 institutional holders of Corbus Pharmaceuticals Holdings, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 9.2%
- Days to cover
- 5.3
- Shares short
- 1,407,889
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CRBP short interestGovernance
Frequently asked questions
What is the AI investment thesis for Corbus Pharmaceuticals Holdings, Inc.?
Corbus Pharmaceuticals Holdings, Inc. (CRBP) is a clinical-stage biopharmaceutical company developing therapies in oncology and obesity, with lead programs including a Nectin-4-targeted ADC (CRB-701) and a peripherally restricted CB1 inverse agonist (CRB-913).
Who is the CEO of Corbus Pharmaceuticals Holdings, Inc.?
Dr. Yuval Cohen Ph.D. is the chief executive officer of Corbus Pharmaceuticals Holdings, Inc. (CRBP).
Where is Corbus Pharmaceuticals Holdings, Inc. headquartered?
Corbus Pharmaceuticals Holdings, Inc. (CRBP) is headquartered in Norwood, MA, United States.
What therapeutic areas does Corbus Pharmaceuticals Holdings, Inc. focus on?
Corbus Pharmaceuticals Holdings, Inc. develops therapies across Oncology, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.